University of Nottingham

The University of Nottingham is a prominent institution known for its comprehensive and research-led approach to education. With a strong commitment to internationalization, it attracts top students and staff globally, ensuring a rich academic experience. The university operates Nottingham University Business School, which has campuses in the UK, China, and Malaysia, and is recognized for its influential research in areas such as banking, finance, entrepreneurship, and business sustainability. The school maintains strong ties with the corporate sector and offers high-quality teaching programs that prepare students for success in an increasingly global environment. Additionally, the University manages an endowment fund that supports scholarships, research, and various academic initiatives, reinforcing its dedication to educational excellence and public service.

Trevor Farren

Director of the Business Partnership Unit

9 past transactions

Cheesecake Energy

Venture Round in 2020
Cheesecake Energy is developing advanced thermal and compressed air energy systems to store energy from intermittent renewables, turning them into reliable power on-demand.

NuVision

Venture Round in 2019
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

One Third Stories

Seed Round in 2018
One Third Stories makes learning a language as simple as reading a story, one that start in English and end in a different language by utilising their innovative Clockwork Methodology®. These are delivered as part of a monthly subscription box for parents and their kids to embark on a language learning adventure.

NuVision

Seed Round in 2018
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

One Third Stories

Convertible Note in 2016
One Third Stories makes learning a language as simple as reading a story, one that start in English and end in a different language by utilising their innovative Clockwork Methodology®. These are delivered as part of a monthly subscription box for parents and their kids to embark on a language learning adventure.

Monica Healthcare

Seed Round in 2015
Based in the United Kingdom, Monica Healthcare is developing a series of innovative wearable devices that will use wireless technologies to facilitate globally accessible obstetric services in the home and hospital. The patented technology is based on the acquisition of electro-physiological signals that can be passively detected by electrodes positioned on the maternal abdomen.

Exonate

Seed Round in 2013
Exonate Limited is a biotechnology company focused on the discovery and development of small molecule drugs that target alternative mRNA splicing, specifically in the field of ophthalmology. Founded in 2013 and based in Duxford, United Kingdom, with a research laboratory in Nottingham, Exonate is dedicated to addressing conditions such as diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD), which are significant causes of vision loss. The company's lead program aims to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) by selectively targeting the splicing mechanisms mediated by serine/threonine-protein kinase 1 (SRPK1). Exonate has developed a pipeline of small molecule inhibitors that have shown promising efficacy in preclinical models. The company has completed an optimization program supported by the Wellcome Trust, leading to the nomination of a pre-clinical candidate drug. Exonate is guided by an experienced management team with expertise in medicine and drug development, and it aims to apply for regulatory evaluation to advance its therapeutic candidates into clinical trials.

Monica Healthcare

Venture Round in 2009
Based in the United Kingdom, Monica Healthcare is developing a series of innovative wearable devices that will use wireless technologies to facilitate globally accessible obstetric services in the home and hospital. The patented technology is based on the acquisition of electro-physiological signals that can be passively detected by electrodes positioned on the maternal abdomen.

Critical Pharmaceuticals

Series B in 2007
Critical Pharmaceuticals Limited is a biotechnology company based in Nottingham, United Kingdom, that specializes in the development of biological drug products using innovative drug delivery technologies. Founded in 2002 by Professor Steve Howdle, the company focuses on non-invasive nasal delivery and sustained release formulations for proteins, peptides, and small molecules. Its proprietary technologies, CriticalSorb and CriticalMix, facilitate the nasal delivery of biologics and the manufacture of depot products that allow for infrequent injections. The company's product pipeline includes CP024, a nasal growth hormone for growth hormone deficiency; CP046, a nasal treatment for osteoporosis; and CP057, a sustained-release formulation of Bevacizumab for age-related macular degeneration, among others. However, as of July 31, 2017, Critical Pharmaceuticals Limited has entered liquidation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.